Emergent BioSolutions | EBS - SCHULD





SCHULD Veränderung Datum
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Akebia Therapeutics USD 46.51M 7.82M 2025-03
ALKERMES USD 1.58B 1.51B 2026-03
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amarin USD 0 0 2025-03
ANI Pharmaceuticals USD 617.04M 3.28M 2025-12
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Coherus Biosciences USD 294.92M 1.25M 2025-03
Emergent BioSolutions USD 903.2M 495.2M 2023-06
Exelixis USD 169.54M 3.5M 2026-03
Glaxosmithkline GBP 17.75B 396M 2025-09
Heron Therapeutics USD 149.65M 157K 2024-09
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Lexicon Pharmaceuticals USD 99.51M 243K 2023-12
Lonza CHF 4.71B 915M 2024-12
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Myriad Genetics USD 59.3M 19.7M 2025-03
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Pacira USD 367.66M 4.53M 2026-03
Pfizer USD 63.73B 231M 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Sanofi EUR 20.33B 1.43B 2025-12
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12
Xoma USD 120.79M 3.27M 2024-06